What Is Bioavailability?
Bioavailability is the proportion of an administered peptide that reaches systemic circulation in its active form. Subcutaneous injection typically provides 65-95% bioavailability for peptides.
Detailed Explanation
Bioavailability represents how much of the administered dose actually reaches the bloodstream in a biologically active form. For peptides, bioavailability varies dramatically by route: subcutaneous injection achieves 65-95%, intramuscular injection 75-100%, intranasal delivery 10-30%, and oral administration typically below 5% due to gastrointestinal degradation and first-pass liver metabolism. BPC-157 is a notable exception with demonstrated oral activity in research. Factors affecting bioavailability include molecular size, enzymatic stability, lipophilicity, and formulation. Research efforts to improve oral bioavailability include enteric coatings, protease inhibitors, permeation enhancers, and nanoparticle delivery systems.
Related Peptides
Related Terms
Subcutaneous Injection
A subcutaneous injection delivers a substance into the fatty tissue layer between the skin and muscle. This is the most common administration route for research peptides.
Half-Life
A peptide's half-life is the time it takes for half of the administered dose to be cleared from the bloodstream. Half-life determines how frequently a peptide needs to be administered.
Intramuscular Injection
An intramuscular (IM) injection delivers a substance directly into muscle tissue. Some peptides use IM injection for faster absorption compared to subcutaneous routes.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.